Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients

Zellner, Maria; Baureder, Michael; Rappold, Eduard; Bugert, Peter; Kotzailias, Nicole; Babeluk, Rita; Baumgartner, Roland; Attems, Johannes; Gerner, Christopher; Jellinger, K. A.; Roth, Erich; Oehler, Rudolf; Umlauf, Ellen

doi:10.1016/j.jprot.2012.01.014

Cited by 49 publications

(32 citation statements)

References 71 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With age, the concentration of MAO-B in the brain increases (Oreland & Gottfries, 1986). A number of studies in patients with AD have shown that up-regulated MAO is a reasonable biomarker for the disease (Sparks, Woeltz, & Markesbery, 1991;Oreland & Gottfries, 1986;Sherif, Gottfries, Alafuzoff, & Oreland, 1992) with levels significantly up-regulated to as much as 30% (Zellner et al, 2012). Such elevated and up-regulated levels of MAO may contribute to the oxidative stress and cognitive impairment through neuroinflammation as MAO generates hydrogenperoxide and ammonia which are among the main culprits contributing to the formation of amyloid plaques (Huang et al, 2012;Zheng, Fridkin, & Youdim, 2012).…”

Section: Alzheimer's Disease (Ad)mentioning

confidence: 99%

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Entzeroth¹,

Ratty²

2017

OJD

View full text Add to dashboard Cite

Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of major depressive disorders and treatment-resistant depression, they became less a therapeutic choice for the physicians mostly due to severe side effects, such as liver failure and hypertensive crisis associated specifically with the first generation of inhibitors. Nevertheless, this class of drugs is still being used for treatment specifically as more selective and reversible inhibitors became available and will provide clinicians with additional treatment options. The current review revisits monoamine oxidase inhibitors and their potential in the treatment of human diseases, such as anxiety, depression, mood and personality disorders, and pain and introduces current ideas and developments.

show abstract

Section: Alzheimer's Disease (Ad)mentioning

confidence: 99%

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Entzeroth¹,

Ratty²

2017

OJD

View full text Add to dashboard Cite

show abstract

“…On the basis of these data, the next steps include comparison of patients with genetic or other clinical conditions affecting platelet function, studies into PTMs, and investigation of the effects of age, sex, and medications on the platelet proteome. 126,127 Subproteome evaluations provide insight into subcellular distribution of proteins and have also been undertaken successfully for platelets. 128 Proteomics is most effective when combined with other technologies or approaches rather than used as a stand-alone method.…”

Section: The Human Proteomementioning

confidence: 99%

Transformative Impact of Proteomics on Cardiovascular Health and Disease

Lindsey¹,

Mayr²,

Gomes³

et al. 2015

Circulation

143

View full text Add to dashboard Cite

Abstract-The year 2014 marked the 20th anniversary of the coining of the term proteomics. The purpose of this scientific statement is to summarize advances over this period that have catalyzed our capacity to address the experimental, translational, and clinical implications of proteomics as applied to cardiovascular health and disease and to evaluate the current status of the field. Key successes that have energized the field are delineated; opportunities for proteomics to drive basic science research, facilitate clinical translation, and establish diagnostic and therapeutic healthcare algorithms are discussed; and challenges that remain to be solved before proteomic technologies can be readily translated from scientific discoveries to meaningful advances in cardiovascular care are addressed. Proteomics is the result of disruptive technologies, namely, mass spectrometry and database searching, which drove protein analysis from 1 protein at a time to protein mixture analyses that enable large-scale analysis of proteins and facilitate paradigm shifts in biological concepts that address important clinical questions. Over the past 20 years, the field of proteomics has matured, yet it is still developing rapidly. The scope of this statement will extend beyond the reaches of a typical review article and offer guidance on the use of next-generation proteomics for future scientific discovery in the basic research laboratory and clinical settings.

show abstract

“…Later work has established that it is MAO B activity that increases with age in human brain (associated with gliosis) and is elevated in several degenerative diseases. Recently, a range of experimental techniques have been used to demonstrate increased MAO B activity in Huntington's, Alzheimer's and Parkinson's diseases (Kennedy et al, 2003, Zellner et al, 2012, Woodard et al, 2014, Ooi et al, 2015. For example, in a new approach, genes related to the dopaminergic system were studied in iPSC neurons from twins without and with PD.…”

Section: Mao Influences the Monoamine Levels In Brainmentioning

confidence: 99%

Molecular aspects of monoamine oxidase B

Ramsay

2016

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

Graphical abstract Highlights• MAO B activity depends on both amine and oxygen concentrations KeywordsMonoamine oxidase B; kinetics; drug design; neurotransmitter levels; platelet AbbreviationsAlzheimer's Disease, AD; Parkinson's Disease, PD; dopamine transporter, DAT; serotonin transporter, SERT; noradrenaline transporter, NET; the vesicular transporter, VMAT; Gprotein coupled receptor, GPCR; induced pluripotent stem cells, iPSC; serotonin reuptake inhibitor, SSRI; brain-derived neurotrophic factor, BDNF; multi-target designed ligands, MTDL; IC 50 , the concentration of compound required to inhibit a specified assay by 50%; K i , a kinetically measured inhibitor dissociation constant. Word count -approx 5490 (excluding references). Abstract 196 words.3

show abstract

Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients

Cited by 49 publications

References 71 publications

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Transformative Impact of Proteomics on Cardiovascular Health and Disease

Molecular aspects of monoamine oxidase B

Contact Info

Product

Resources

About